Tests AL-001 eye injection in adults with wet age-related macular degeneration
Tests AL-001 eye injection against aflibercept in adults with wet macular degeneration.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 85 with active wet age-related macular degeneration (wAMD) in the eye being studied, whose eye has responded to anti-VEGF injections.
- Age
- 50 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Active choroidal neovascularization (CNV) under the centre of the retina (subfoveal) in the study eye, caused by wAMD.
- Earlier treatment
- The study eye must have responded to anti-VEGF injections.
Main reasons for not taking part
- CNV or macular edema in the study eye not caused by wAMD
- Other eye conditions that may affect central vision in the study eye
- Uncontrolled glaucoma in the study eye
- Past vitreoretinal surgery or glaucoma filtering surgery in the study eye
- Malignant tumor in any eye, such as eye lymphoma or choroidal melanoma
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT06839339, who can take part
Where in China
- Chinese Academy of Medical Sciences & Peking Union HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Beijing Anlong Biopharmaceutical Co., Ltd.
- Trial code
- NCT06839339
- Record updated
- 21 February 2025
- Original description
This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.Read full original descriptionShow less
A Phase II, Randomized, Positive-controlled, Multicenter Clinical Study to Evaluate the Efficacy and Safety of Single Suprachoroidal Space Injection of AL-001 Ophthalmic Injection in Subjects with Wet Age-related Macular Degeneration (wAMD)
This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration. Eligible patients, who meet the inclusion/exclusion criteria and have shown an anatomic response to an anti-VEGF (Vascular Endothelial Growth Factor) injection, will be randomized in Cohorts 1 and 2 to receive AL-001 administered via suprachoroidal space injection, Cohort 3 to receive Aflibercept.
Inclusion: Age≥ 50 and ≤ 85; The study eye was diagnosed with subfoveal active choroidal neovascularization (CNV) lesions secondary to wAMD; The study eye has response to anti-VEGF injections; The subject or their legal representative agrees to participate in this study and signs a written ICF.
Exclusion: Non-wAMD induced eye conditions that may affect central vision or medical history that may seriously affect central vision in the study eye; History of vitreoretinal surgery, antiglaucoma trabeculectomy, or other anti-glaucoma filtering surgery in the study eye; Malignant tumor in any eye, including but not limited to eye lymphoma or choroidal melanoma; Other conditions that may affect compliance or may not be suitable to participate in this trial in the opinion of investigator; Non-wAMD induced CNV or macular edema in the study eye; Uncontrolled glaucoma in the study eye; Refractive interstitial opacity that significantly affects visual function assessment or fundus examination in the study eye; Ametropia (high myopia or high hyperopia) > 8.0D in the study eye, or significant posterior scleral staphyloma in the study eye; None of intraocular inflammation in the study eye.